In a patient with clinically documented atherosclerosis and a low-density lipoprotein cholesterol of 3.13 mmol/L, should a statin be started?

Yes, Start High-Intensity Statin Therapy Immediately

In a patient with clinically documented atherosclerosis and an LDL-C of 3.13 mmol/L (121 mg/dL), you should absolutely start high-intensity statin therapy immediately with a goal to reduce LDL-C by ≥50% and achieve a target of <1.4 mmol/L (55 mg/dL). 1, 2

Rationale

Your patient has established atherosclerotic cardiovascular disease (ASCVD), which automatically places them in the very high-risk category regardless of their current LDL-C level. The presence of clinical atherosclerosis is the critical factor here, not the baseline LDL-C value.

Guideline-Directed Therapy

Both major international guidelines are unequivocal on this point:

• 2019 ACC/AHA Guidelines: Patients with clinical ASCVD should receive high-intensity statin therapy or maximally tolerated statin therapy to lower LDL-C by ≥50%, regardless of baseline LDL-C 1

• 2024 ESC Guidelines: All patients with chronic coronary syndrome (a form of clinical ASCVD) require high-intensity statin therapy up to the highest tolerated dose, with an LDL-C goal of <1.4 mmol/L (55 mg/dL) and a ≥50% reduction from baseline (Class I, Level A recommendation) 2

Treatment Algorithm

Step 1: Initiate High-Intensity Statin

• Start atorvastatin 40-80 mg daily OR rosuvastatin 20-40 mg daily
• These doses achieve 45-50% LDL-C reduction on average 2
• With your patient's baseline of 3.13 mmol/L, a 50% reduction would bring LDL-C to approximately 1.57 mmol/L

Step 2: Reassess in 4-12 Weeks

• If LDL-C remains ≥1.4 mmol/L despite maximally tolerated statin, add ezetimibe (Class I, Level B recommendation) 2
• Ezetimibe provides an additional 20-25% LDL-C reduction 2

Step 3: Consider PCSK9 Inhibitor if Needed

• If LDL-C remains ≥1.4 mmol/L on statin plus ezetimibe, add a PCSK9 inhibitor (alirocumab or evolocumab) (Class I, Level A recommendation) 2
• PCSK9 inhibitors reduce LDL-C by an additional 60% 2

Evidence for Benefit

The evidence supporting aggressive LDL-C lowering in established ASCVD is robust. Meta-analyses demonstrate that for every 1.0 mmol/L reduction in LDL-C:

• 22% reduction in major vascular events
• 10% reduction in all-cause mortality
• 20% reduction in coronary heart disease mortality 2

The relationship is log-linear: the more you lower LDL-C, the greater the risk reduction 1

Common Pitfalls to Avoid

1. Don't wait to see if lifestyle modifications alone will work - Your patient has established disease and needs immediate pharmacotherapy

2. Don't use moderate-intensity statins - High-intensity therapy is the standard of care for secondary prevention

3. Don't stop at "normal" LDL-C levels - The target is <1.4 mmol/L, not just below population averages

4. Don't delay combination therapy - If the patient doesn't reach goal on maximally tolerated statin alone, add ezetimibe promptly rather than waiting months

Very High-Risk Considerations

If your patient has very high-risk features (history of multiple major ASCVD events or 1 major event plus multiple high-risk conditions), consider an even more aggressive LDL-C threshold of <1.0 mmol/L (40 mg/dL) 2. In such cases, you may need to proceed directly to combination therapy with statin plus ezetimibe, and potentially add a PCSK9 inhibitor if goals aren't met 1, 2.